Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc. AGNPF


Primary Symbol: C.AGN

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Recent & Breaking News (CSE:AGN)

Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate

GlobeNewswire July 5, 2022

Algernon Pharmaceuticals Inc. (CSE:AGN) closes public offering of units

Azuka Onwuka July 4, 2022

Algernon Pharmaceuticals Announces Closing of Public Offering of Units

GlobeNewswire July 4, 2022

Algernon Pharmaceuticals (CSE:AGN) announces pricing of public offering

John Ballem  June 27, 2022

Algernon Pharmaceuticals Announces Pricing of Public Offering of Units

GlobeNewswire June 27, 2022

Algernon Pharmaceuticals (CSE:AGN) receives patent for Ifenprodil

John Ballem  June 22, 2022

Algernon Pharmaceuticals Announces Issuance of Patent for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

GlobeNewswire June 22, 2022

Algernon (CSE:AGN) receives requests for ongoing supply of Ifenprodil from study participants

Azuka Onwuka June 21, 2022

Algernon Announces Patients Requested Ongoing Supply of Ifenprodil after IPF and Chronic Cough Phase 2 Study Ended

GlobeNewswire June 21, 2022

Algernon Pharmaceuticals (CSE:AGN) announces public offering of units

John Ballem  June 16, 2022

Algernon Pharmaceuticals Announces Public Offering of Units

GlobeNewswire June 15, 2022

Algernon Pharmaceuticals (CSE:AGN) locks in Phase 2 results of IPF & chronic cough study

Jonathon Brown June 13, 2022

Algernon Pharmaceuticals Announces Database Lock in Phase 2 Study of IPF and Chronic Cough

GlobeNewswire June 13, 2022

Algernon Pharmaceuticals (CSE:AGN) treats last patient in phase 2 IPF and chronic cough study

Trevor Abes  May 5, 2022

Algernon Pharmaceuticals Announces Last Patient Treated in Phase 2 Study of IPF and Chronic Cough

GlobeNewswire May 5, 2022

Algernon Pharmaceuticals (CSE:AGN) reports positive findings in lead chronic kidney disease drug, Repirinast

Brieanna McCutcheon  April 26, 2022

Algernon Pharmaceuticals Announces Lead Chronic Kidney Disease Drug Repirinast Reduced Fibrosis by 56% in a Preclinical NASH Study

GlobeNewswire April 26, 2022

Algernon Pharmaceuticals Begins Manufacturing of Repirinast and Launches New Chronic Kidney Disease Research Program

GlobeNewswire February 23, 2022

Canadian Pharma Co. Advances Chronic Cough Study

Stockhouse Editorial February 4, 2022

Algernon Pharmaceuticals (CSE:AGN) completes enrollment in its Phase 2 study of Ifenprodil

John Ballem  February 4, 2022